Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 7, 2011

Orphazyme Closes €14M Financing to Advance Work in Lysosomal Storage Diseases

  • Orphazyme closed a €14 million ($19.6 million) series A financing round. Proceeds will go toward advancing the company’s lead program, Orph-001, into clinical development. Aescap Venture joined existing investors Novo and Sunstone Capital in the round.

    Orphazyme develops treatments for lysosomal storage diseases and has two projects in preclinical development. Orph-001 is a recombinant version of human HSP70. It is currently being tested in vivo in animal models in collaboration with academic laboratories.

    Orphazyme is based on discoveries of its scientific founders, Marja Jäättela, M.D., and Thomas Kirkegaard Jensen, Ph.D., a postdoc at the Danish Cancer Society (Kræftens Bekæmpelse). Novo provided grant funding before becoming a shareholder and was a founding investor in Orphazyme.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »